Yervoy clinical trials
Yervoy is named as an intervention in 65 current clinical trials in our USA, Israel, Canada, Mexico, France, Australia, Spain, UK, Italy, China, Germany, Netherlands, Japan, Poland, South Korea, Taiwan, Brazil, Switzerland, Czechia, Belgium, Austria, Denmark, Norway, Ireland, Singapore, Egypt, Turkey, Portugal and Sweden registers. 26 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is National Cancer Institute (NCI) (16). The most-studied condition is Renal Cell Carcinoma.
Patient leaflets for Yervoy
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Yervoy
65 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Yervoy
133 conditionsAll 133 conditions
| Condition (as registered) | Trials |
|---|---|
| Renal Cell Carcinoma | 4 |
| Clinical Stage III Cutaneous Melanoma AJCC v8 | 3 |
| Clinical Stage IV Cutaneous Melanoma AJCC v8 | 3 |
| Hepatocellular Carcinoma (HCC) | 3 |
| Advanced Melanoma | 3 |
| Metastatic Melanoma | 3 |
| Solid Tumor | 3 |
| Recurrent Melanoma | 3 |
| Metastatic Uveal Melanoma | 2 |
| Brain Metastases, Adult | 2 |
| Advanced Solid Tumor | 2 |
| Melanoma | 2 |
| Renal Cancer | 2 |
| Melanoma of Unknown Primary | 2 |
| Stage III Cutaneous Melanoma AJCC v7 | 2 |
| Advanced Renal Cell Carcinoma (RCC) | 1 |
| Metastatic Renal Cell Carcinoma | 1 |
| Stage III Renal Cell Cancer AJCC v8 | 1 |
| Stage IV Renal Cell Cancer AJCC v8 | 1 |
| Unresectable Renal Cell Carcinoma | 1 |
| Metastatic Cutaneous Melanoma | 1 |
| Metastatic Mucosal Melanoma | 1 |
| Unresectable Pleural Mesothelioma | 1 |
| Melanoma (Skin Cancer) | 1 |
| Skin Cancer | 1 |
| Renal Cell Carcinoma (RCC) | 1 |
| Metastatic Castration-Resistant Prostate Cancer (mCRPC) | 1 |
| Urothelial Carcinoma (UC) | 1 |
| Melanoma, Cutaneous Malignant | 1 |
| Mucosal Melanoma | 1 |
| Carcinoma, Hepatocellular | 1 |
| Hepatocellular Cancer | 1 |
| Hepatocellular Carcinoma | 1 |
| Unresectable Hepatocellular Carcinoma | 1 |
| Diffuse Astrocytoma, IDH-Mutant | 1 |
| Glioblastoma, IDH-wildtype | 1 |
| Cervical Cancer | 1 |
| Advanced Cancer | 1 |
| Metastasis | 1 |
| Carcinoma, Renal Cell | 1 |
| Advanced Renal Cell Carcinoma | 1 |
| Renal Neoplasm | 1 |
| Colorectal Neoplasms | 1 |
| Non-Small Cell Lung Cancer | 1 |
| Recurrent Hepatocellular Cancer | 1 |
| Gastric Cancer | 1 |
| Localized Oesogastric Adenocarcimona | 1 |
| MSI and or dMMR | 1 |
| Metastatic Kidney Cancer | 1 |
| Metastatic Kidney Carcinoma | 1 |
| Metastatic Colorectal Cancer | 1 |
| Non Small Cell Lung Cancer | 1 |
| Lung Cancer | 1 |
| Cancer | 1 |
| Cancer, Lung | 1 |
| Cancer of Lung | 1 |
| Mesothelioma | 1 |
| Metastatic Breast Cancer | 1 |
| Cancer of Rectum | 1 |
| Malignant Melanoma | 1 |
| Clear Cell Renal Cell Carcinoma | 1 |
| Metastatic Malignant Neoplasm in the Bone | 1 |
| Metastatic Malignant Neoplasm in the Lymph Nodes | 1 |
| Metastatic Malignant Neoplasm in the Soft Tissue | 1 |
| Melanoma Stage Iv | 1 |
| Advanced Malignant Solid Neoplasm | 1 |
| Metastatic Malignant Solid Neoplasm | 1 |
| Unresectable Malignant Solid Neoplasm | 1 |
| Stage IIIB Cutaneous Melanoma AJCC v7 | 1 |
| Stage IIIC Cutaneous Melanoma AJCC v7 | 1 |
| Advanced Hepatocellular Carcinoma | 1 |
| Stage III Hepatocellular Carcinoma AJCC v8 | 1 |
| Stage IV Hepatocellular Carcinoma AJCC v8 | 1 |
| Anal Canal Squamous Cell Carcinoma | 1 |
| Metastatic Anal Canal Carcinoma | 1 |
| Stage IV Anal Cancer AJCC v8 | 1 |
| Recurrent Squamous Cell Lung Carcinoma | 1 |
| Stage IV Squamous Cell Lung Carcinoma AJCC v7 | 1 |
| Locally Advanced Extraskeletal Myxoid Chondrosarcoma | 1 |
| Locally Advanced Leiomyosarcoma | 1 |
| Locally Advanced Liposarcoma | 1 |
| Locally Advanced Undifferentiated Pleomorphic Sarcoma | 1 |
| Metastatic Large Cell Neuroendocrine Carcinoma | 1 |
| Metastatic Neuroendocrine Carcinoma | 1 |
| Metastatic Neuroendocrine Neoplasm | 1 |
| Metastatic Small Cell Neuroendocrine Carcinoma | 1 |
| Pancreatic Adenocarcinoma | 1 |
| Stage II Pancreatic Cancer AJCC v8 | 1 |
| Stage III Pancreatic Cancer AJCC v8 | 1 |
| Stage IV Pancreatic Cancer AJCC v8 | 1 |
| Autoimmune Disease | 1 |
| Crohn Disease | 1 |
| Dermatomyositis | 1 |
| Hematopoietic and Lymphoid Cell Neoplasm | 1 |
| Uterine Cervical Neoplasms | 1 |
| Renal Cancer Metastatic | 1 |
| Endometrial Adenocarcinoma | 1 |
| Endometrial Clear Cell Adenocarcinoma | 1 |
| Endometrial Dedifferentiated Carcinoma | 1 |
| Endometrial Endometrioid Adenocarcinoma | 1 |
| Acinar Cell Carcinoma | 1 |
| Adenoid Cystic Carcinoma | 1 |
| Adrenal Cortical Carcinoma | 1 |
| Adrenal Gland Pheochromocytoma | 1 |
| Stage IV Cutaneous Melanoma AJCC v6 and v7 | 1 |
| Recurrent Classic Hodgkin Lymphoma | 1 |
| Refractory Classic Hodgkin Lymphoma | 1 |
| Nasopharyngeal Carcinoma | 1 |
| Melanoma Brain Metastases | 1 |
| Brain Metastases | 1 |
| Advanced Biliary Tract Cancer | 1 |
| Neuroendocrine Tumors | 1 |
| Female Reproductive System Neoplasm | 1 |
| MSI-H Solid Malignant Tumor | 1 |
| Papillary Renal Cell Carcinoma | 1 |
| Unclassified Renal Cell Carcinoma | 1 |
| Translocation Renal Cell Carcinoma | 1 |
| Chromophobe Renal Cell Carcinoma | 1 |
| Genitourinary Cancer | 1 |
| Adrenocortical Carcinoma | 1 |
| Non-urothelial Bladder | 1 |
| Non-urothelial Upper Tract | 1 |
| Pancreatic Cancer | 1 |
| Metastatic Pancreatic Cancer | 1 |
| Bladder Adenocarcinoma | 1 |
| Bladder Clear Cell Adenocarcinoma | 1 |
| Bladder Mixed Adenocarcinoma | 1 |
| Bladder Neuroendocrine Carcinoma | 1 |
| Previously Treated Myelodysplastic Syndrome | 1 |
| Recurrent Acute Myeloid Leukemia | 1 |
| Recurrent Acute Myeloid Leukemia, Myelodysplasia-Related | 1 |
| Recurrent Myelodysplastic Syndrome | 1 |
| Metastatic Microsatellite Stable Colorectal Cancer | 1 |
Sponsors
lead sponsor per trial+ 24 more sponsors in the trial list above.
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Yervoy trials
How many clinical trials are testing Yervoy?
65 current trials in our USA, Israel, Canada, Mexico, France, Australia, Spain, UK, Italy, China, Germany, Netherlands, Japan, Poland, South Korea, Taiwan, Brazil, Switzerland, Czechia, Belgium, Austria, Denmark, Norway, Ireland, Singapore, Egypt, Turkey, Portugal and Sweden registers name Yervoy as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Yervoy trials recruiting patients?
Yes. 26 of the 65 trials are recruiting: 12 with sites in USA, 5 with sites in Israel, 6 with sites in Canada, 4 with sites in Mexico, 8 with sites in France, 8 with sites in Australia, 6 with sites in Spain, 5 with sites in UK, 4 with sites in Italy, 5 with sites in China, 5 with sites in Germany, 4 with sites in Netherlands, 5 with sites in Japan, 2 with sites in Poland, 2 with sites in South Korea, 2 with sites in Taiwan, 1 with sites in Brazil, 2 with sites in Switzerland, 2 with sites in Czechia, 1 with sites in Belgium, 2 with sites in Austria, 2 with sites in Denmark, 1 with sites in Norway, 2 with sites in Ireland and 1 with sites in Singapore. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Yervoy clinical trials?
National Cancer Institute (NCI) (16), Bristol-Myers Squibb (5), NRG Oncology (2) and Exelixis (2), among 39 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Are there Yervoy clinical trials in Ireland?
Yes. 3 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Yervoy works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Yervoy works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Yervoy (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.